IVIG therapy and use
Dr. Rae Bacharach discusses intravenous or subcutaneous immunoglobulin therapy in immune-mediated neurologic conditions.
2 Elo 20191min
Application of the McDonald criteria in the diagnosis of MS
Dr. Rae Bacharach discusses important points regarding application of the 2017 McDonald criteria for the diagnosis of MS.
1 Elo 20192min
Oligoclonal bands and differentiation
Dr. Rae Bacharach discusses oligoclonal bands in MS and other conditions and differentiating types of bands.
31 Heinä 20191min
CDC's Guideline on Pediatric Mild Traumatic Brain Injury: Recommendations for Neurologists
Dr. Barbara Weissman discusses the main points from her Neurology: Clinical Practice paper on recommendations for neurologists on the CDC's Guideline on Pediatric Mild Traumatic Brain Injury.
30 Heinä 20191min
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
Dr. Geoffrey Donnan discusses the main takeaways from his study on thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. Read his NEJM article here: https://www.nejm.org/doi/pd...
29 Heinä 20192min
Continuum Pearls: Disease-Modifying Therapies in MS
Dr. Robert H. Gross discusses disease-modifying therapies in MS in the third part of a three-part series. To learn more, read the article "Monitoring, Switching, and Stopping Multiple Sclerosis Diseas...
25 Heinä 20191min
Continuum Pearls: Disease-Modifying Therapies in MS, pt. 2
Dr. Robert H. Gross discusses disease-modifying therapies in MS in the second part of a three-part series. To learn more, read the article "Monitoring, Switching, and Stopping Multiple Sclerosis Disea...
24 Heinä 20193min
Determining clinically meaningful decline in preclinical Alzheimer disease
Dr. Philip Insel provides the main findings of his paper on determining clinically meaningful decline in preclinical Alzheimer disease.
23 Heinä 20191min
